This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold IART Stock in Your Portfolio Now
by Zacks Equity Research
Integra's growth within its Tissue Technologies business segment bolsters investors' confidence in the stock.
Reasons to Retain AMED Stock in Your Portfolio Now
by Zacks Equity Research
Amedisys' expected merger with UnitedHealth Group's Optum brings optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
by Zacks Equity Research
Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors.
Here's Why You Should Add HAE Stock to Your Portfolio Now
by Zacks Equity Research
Strong prospects for the Plasma franchise and favorable solvency bode well for Haemonetics.
The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories
by Zacks Equity Research
Veracyte, Omnicell, Masimo and Abbott Laboratories are included in this Analyst Blog.
4 Healthcare Technology Innovators to Invest in Before the New Year
by Urmimala Biswas
Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT.
Why Omnicell (OMCL) Might be Well Poised for a Surge
by Zacks Equity Research
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
New Strong Buy Stocks for December 18th
by Zacks Equity Research
LTM, OMCL, DXPE, ALL and CRS have been added to the Zacks Rank #1 (Strong Buy) List on December 18, 2024.
What Makes Omnicell (OMCL) a New Strong Buy Stock
by Zacks Equity Research
Omnicell (OMCL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for December 12th
by Zacks Equity Research
ZIM, OMCL and FOA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 12, 2024.
Omnicell Introduces OmniSphere Platform, Stock to Gain
by Zacks Equity Research
Omnicell introduces OmniSphere. Additionally, the company showcases a full portfolio of outcomes-centric solutions at the ASHP Midyear 2024.
New Strong Buy Stocks for December 12th
by Zacks Equity Research
NBBK, OMCL, ZIM, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on December 12, 2024.
The Zacks Analyst Blog Highlights Inspire Medical, Omnicell, Talkspace, Butterfly Network and Clover Health
by Zacks Equity Research
Inspire Medical, Omnicell, Talkspace, Butterfly Network and Clover Health are included in this Analyst Blog.
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?
by Zacks Equity Research
Haemonetics inks a new agreement to sell its whole blood assets to GVS. The transaction is expected to be closed in the first quarter of 2025.
5 Medical Info System Stocks to Buy for a Stable Portfolio in 2025
by Nalak Das
Five medical info systems stocks have strong potential for 2025. These are: INSP, OMCL, TALK, BFLY, CLOV.
Why Is Omnicell (OMCL) Down 0.4% Since Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Believe Omnicell (OMCL) Could Rally 26.73%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Omnicell (OMCL) points to a 26.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Add OMCL Stock to Your Portfolio Now
by Zacks Equity Research
A robust Advanced Services portfolio and long-term growth initiatives bode well for Omnicell.
Surging Earnings Estimates Signal Upside for Omnicell (OMCL) Stock
by Zacks Equity Research
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CLOV Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
by Zacks Equity Research
The continued strength in Clover Health's offerings is likely to have driven the company's performance in the third quarter.
OMCL Stock Soars on Q3 Earnings & Revenue Beat, '24 EPS View Raised
by Zacks Equity Research
Omnicell continues its trend of impressive results in the third quarter of 2024.
Omnicell, Inc. (OMCL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Omnicell (OMCL) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 36.59% and 1.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell
by Zacks Equity Research
Medical Systems, 10x Genomics and Omnicell have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks to Gain From Healthcare Digitization
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, 10x Genomics and Omnicell are expected to gain from the GenAI wave.